DAIVOBET 50 micrograme/0,5mg/g România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

daivobet 50 micrograme/0,5mg/g

leo laboratories ltd. - irlanda - combinatii (calcipotriolum+betamethasonum) - unguent - 50micrograme/0,5mg/g - antipsoriazice de uz local alte antipsoriazice de uz local

DAIVOBET 50 micrograme/0,5 mg/g România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

daivobet 50 micrograme/0,5 mg/g

leo pharma a/s - danemarca - combinatii (calcipotriolum+betamethasonum) - gel - 50micrograme/0,5mg/g - antipsoriazice de uz local alte antipsoriazice de uz local

ENSTILUM 50 micrograme/0,5 mg/g România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

enstilum 50 micrograme/0,5 mg/g

colep laupheim gmbh & co. kg - germania - combinatii (calcipotriolum+betamethasonum) - spuma cut. - 50micrograme/0,5mg/g - antipsoriazice de uz local alte antipsoriazice de uz local

XAMIOL 50 micrograme/ 0,5 mg/g România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

xamiol 50 micrograme/ 0,5 mg/g

leo pharma a/s - combinatii (calcipotriolum+betamethasonum) - gel - 50micrograme/0,5mg/g - antipsoriazice de uz local alte antipsoriazice de uz local

ROCALTROL 0,25 micrograme România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rocaltrol 0,25 micrograme

roche romania s.r.l. - calcitriolum - caps. moi - 0,25micrograme - vitamina a si d, incl. combinatii vitamina d si analogi

Crysvita Uniunea Europeană - română - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - medicamente pentru tratamentul bolilor osoase - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.